This paper was published through Galoá and has a deposited DOI. To cite this paper, use one of the standards below:
In case you are one of the co-authors and want to register this paper in your Lattes, use the following code: doi > 10.17648/bctrims-2023-167440
If you've NEVER registered a DOI in your Lattes, check our tutorial!Introduction: Disease modifying drugs (DMDs) have been shown to reduce relapses and improve survival in patients with multiple sclerosis (MS). However, the impact of discontinuing DMDs in elderly patients with MS, who may have a lower risk of relapse but a higher chance of experiencing DMD-related adverse events, remains unknown, as they are often excluded from clinical trials. Objectives: The aim of this study is to examine the impact of discontinuing DMDs on the clinical course of elderly patients with MS. Methods: We conducted a retrospective observational study using data from MS patients aged over 55 years, from 2015 to 2022 in our service. Age, sex, disease duration, and previous DMD use were extracted from medical records. The primary outcome was the frequency of clinical / radiological disease activity after discontinuing DMDs. We compared patients who discontinued DMDs with those who did not, using Chi-Square and Mann-Whitney U tests in SPSS. Results: As of now, among 30 elderly MS patients, 19 (63.3%) discontinued DMDs and 11 (36.7%) maintained DMDs. After discontinuation, 6 (31.5%) of patients experienced clinical or radiographic disease activity. Patients who discontinued DMDs were significantly older than those who continued the therapy (69.95 vs. 65.00; p=0.047) and both groups had high median EDSS scores (6.5 vs 5.0), long disease duration (29.7 vs 22.7), and no participant who discontinued DMDs were on high-efficacy drugs. However, there were no significant differences in the proportion of female patients or disease duration. Conclusion: The findings of this study suggest that discontinuing DMDs may result in up to one-third of elderly patients with MS experiencing disease activity. However, further research is needed to confirm these findings and identify prognostic factors that may be associated with successful discontinuation of treatment. The study is currently ongoing.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper